uniQure N.V. (QURE) - Stock Analysis
Last updated: Jan 14, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
uniQure’s Phase I/II Huntington’s gene therapy trial showed a 75% slowing of progression, triggering a 250% price surge and near five-year high. Strong FDA alignment for BLA filing and robust capital provide near-term growth catalysts despite technical overbought conditions and dilution risk.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Strong liquidity • Persistent losses • Elevated leverage QURE has a solid near-term liquidity cushion (cash $597m, current ratio 7.12) but ongoing large operating losses, high R&D/SG&A burn and heavy leverage (debt ~$532m vs equity $228.7m) that threaten longer-term solvency and valuation.
Price Behavior
Key Price Behavior Insights: • Support tested • Failed rally • High volatility Support Level: $21.50 Resistance Level: $23.00-$23.50 Over the last month QURE fell below near-term support—dropping from about $25.32 to $21.50 after a larger correction from $30.84—signaling weakening buyer interest and elevated downside risk unless $21.50 holds.
Sentiment & News
Key News Insights: • FDA reversal • Ongoing investigations • Strong trial data uniQure faces simultaneous legal probes and an FDA reversal delaying AMT‑130's BLA despite strong Phase 1/2 efficacy and solid cash reserves, prompting a Type A meeting to seek a regulatory path forward.
AI Summary
QURE's investment case has shifted from clinical optionality to a regulatory‑execution contest where FDA acceptance of AMT‑130's evidentiary package—and the outcome of securities investigations—will deterministically drive timing and valuation, making near‑term upside contingent on proving an approvable, defendable submission rather than additional efficacy signals alone. Investors should treat the next few quarters as binary regulatory readouts: monitor FDA guidance on external controls, legal developments, and cash burn cadence (given high leverage) and avoid buy‑and‑hold exposure until clear regulatory resolution or a partnership de‑risks approval pathways.
Description
uniQure N.V. is a gene therapy company developing treatments for genetic and other severe diseases. Its lead program, etranacogene dezaparvovec (AMT-061), is in the Phase III HOPE-B trial for hemophilia B, and the broader pipeline includes clinical and preclinical candidates targeting central nervous system and neuromuscular disorders such as Huntington’s disease, Parkinson’s disease, temporal lobe epilepsy, ALS and forms of Alzheimer’s, as well as earlier-stage hemophilia approaches. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 29 | Oct 6 | QURE | uniQure N.V. | uniQure’s Phase I/II Huntington’s gene therapy trial showed a 75% slowing of progression, triggering a 250% price surge and near five-year high. Strong FDA alignment for BLA filing and robust capital provide near-term growth catalysts despite technical overbought conditions and dilution risk. | Closed | -10.9% |